- Home
- BOLT vs NCNA Comparison
BOLT vs NCNA Comparison
Compare BOLT & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BOLT | NCNA |
|---|---|---|
| Founded | 2015 | 1997 |
| Country | United States | United Kingdom |
| Employees | N/A | 12 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.5M | 8.4M |
| IPO Year | 2021 | 2017 |
Fundamental Metrics
Financial Performance| Metric | BOLT | NCNA |
|---|---|---|
| Price | $4.56 | $1.95 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $34.00 | N/A |
| AVG Volume (30 Days) | 23.0K | ★ 38.0K |
| Earning Date | 05-13-2026 | 06-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,695,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $133.33 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 0.07 | N/A |
| 52 Week Low | $3.91 | $0.03 |
| 52 Week High | $7.35 | $10.00 |
Technical Indicators
Market Signals| Indicator | BOLT | NCNA |
|---|---|---|
| Relative Strength Index (RSI) | 44.32 | 44.41 |
| Support Level | $4.32 | $1.83 |
| Resistance Level | $5.22 | $2.28 |
| Average True Range (ATR) | 0.37 | 0.16 |
| MACD | -0.04 | -0.01 |
| Stochastic Oscillator | 24.13 | 10.42 |
Price Performance
Historical ComparisonAbout BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States and the United Kingdom.